These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 23555631)

  • 1. Immunogenicity of live attenuated B. pertussis BPZE1 producing the universal influenza vaccine candidate M2e.
    Kammoun H; Roux X; Raze D; Debrie AS; De Filette M; Ysenbaert T; Mielcarek N; Saelens X; Fiers W; Locht C
    PLoS One; 2013; 8(3):e59198. PubMed ID: 23555631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of live attenuated Bordetella pertussis strains expressing the universal influenza vaccine candidate M2e.
    Li R; Lim A; Ow ST; Phoon MC; Locht C; Chow VT; Alonso S
    Vaccine; 2011 Jul; 29(33):5502-11. PubMed ID: 21624415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High immunogenicity of plant-produced candidate influenza vaccine based on the M2e peptide fused to flagellin.
    Mardanova ES; Kotlyarov RY; Kuprianov VV; Stepanova LA; Tsybalova LM; Lomonossoff GP; Ravin NV
    Bioengineered; 2016; 7(1):28-32. PubMed ID: 26710263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protection against influenza A virus by vaccination with a recombinant fusion protein linking influenza M2e to human serum albumin (HSA).
    Mu X; Hu K; Shen M; Kong N; Fu C; Yan W; Wei A
    J Virol Methods; 2016 Feb; 228():84-90. PubMed ID: 26615805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccination with three tandem repeats of M2 extracellular domain fused to Leismania major HSP70 protects mice against influenza A virus challenge.
    Shokouhi H; Farahmand B; Ghaemi A; Mazaheri V; Fotouhi F
    Virus Res; 2018 Jun; 251():40-46. PubMed ID: 29730305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Attenuated Bordetella pertussis BPZE1 as a live vehicle for heterologous vaccine antigens delivery through the nasal route.
    Li R; Lim A; Alonso S
    Bioeng Bugs; 2011; 2(6):315-9. PubMed ID: 22067832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Roles of adjuvant and route of vaccination in antibody response and protection engendered by a synthetic matrix protein 2-based influenza A virus vaccine in the mouse.
    Mozdzanowska K; Zharikova D; Cudic M; Otvos L; Gerhard W
    Virol J; 2007 Oct; 4():118. PubMed ID: 17974006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced cross protection by hetero prime-boost vaccination with recombinant influenza viruses containing chimeric hemagglutinin-M2e epitopes.
    Park BR; Subbiah J; Kim KH; Kwon YM; Oh J; Kim MC; Shin CH; Seong BL; Kang SM
    Virology; 2022 Jan; 566():143-152. PubMed ID: 34929590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin.
    Huleatt JW; Nakaar V; Desai P; Huang Y; Hewitt D; Jacobs A; Tang J; McDonald W; Song L; Evans RK; Umlauf S; Tussey L; Powell TJ
    Vaccine; 2008 Jan; 26(2):201-14. PubMed ID: 18063235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intranasal adenovirus-vectored vaccine for induction of long-lasting humoral immunity-mediated broad protection against influenza in mice.
    Kim EH; Park HJ; Han GY; Song MK; Pereboev A; Hong JS; Chang J; Byun YH; Seong BL; Nguyen HH
    J Virol; 2014 Sep; 88(17):9693-703. PubMed ID: 24920793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protection against multiple influenza A virus strains induced by candidate recombinant vaccine based on heterologous M2e peptides linked to flagellin.
    Stepanova LA; Kotlyarov RY; Kovaleva AA; Potapchuk MV; Korotkov AV; Sergeeva MV; Kasianenko MA; Kuprianov VV; Ravin NV; Tsybalova LM; Skryabin KG; Kiselev OI
    PLoS One; 2015; 10(3):e0119520. PubMed ID: 25799221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant region of hepatitis B core antigen: Broad protective efficacy of particles carrying four copies of M2e.
    Tsybalova LM; Stepanova LA; Kuprianov VV; Blokhina EA; Potapchuk MV; Korotkov AV; Gorshkov AN; Kasyanenko MA; Ravin NV; Kiselev OI
    Vaccine; 2015 Jun; 33(29):3398-406. PubMed ID: 25976545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sublingual immunization with M2-based vaccine induces broad protective immunity against influenza.
    Shim BS; Choi YK; Yun CH; Lee EG; Jeon YS; Park SM; Cheon IS; Joo DH; Cho CH; Song MS; Seo SU; Byun YH; Park HJ; Poo H; Seong BL; Kim JO; Nguyen HH; Stadler K; Kim DW; Hong KJ; Czerkinsky C; Song MK
    PLoS One; 2011; 6(11):e27953. PubMed ID: 22140491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Immunogenicity of recombinant proteins including ectodomain of M2 influenza virus A].
    Stepanova LA; Kovaleva AA; Potapchuk MV; Korotkov AV; Kupriianov VV; Blokhina EA; Kotliarov RIu; Tsybalova LM
    Vopr Virusol; 2013; 58(3):21-5. PubMed ID: 24006628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In contrast to conventional inactivated influenza vaccines, 4xM2e.HSP70c fusion protein fully protected mice against lethal dose of H1, H3 and H9 influenza A isolates circulating in Iran.
    Ebrahimi SM; Dabaghian M; Tebianian M; Jazi MH
    Virology; 2012 Aug; 430(1):63-72. PubMed ID: 22595444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complete protection against a H5N2 avian influenza virus by a DNA vaccine expressing a fusion protein of H1N1 HA and M2e.
    Park KS; Seo YB; Lee JY; Im SJ; Seo SH; Song MS; Choi YK; Sung YC
    Vaccine; 2011 Jul; 29(33):5481-7. PubMed ID: 21664216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant loop region of hepatitis B core antigen: Insertion of multiple copies of M2e increases immunogenicity and protective efficiency.
    Ravin NV; Blokhina EA; Kuprianov VV; Stepanova LA; Shaldjan AA; Kovaleva AA; Tsybalova LM; Skryabin KG
    Vaccine; 2015 Jun; 33(29):3392-7. PubMed ID: 25937448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced influenza virus-like particle vaccines containing the extracellular domain of matrix protein 2 and a Toll-like receptor ligand.
    Wang BZ; Gill HS; Kang SM; Wang L; Wang YC; Vassilieva EV; Compans RW
    Clin Vaccine Immunol; 2012 Aug; 19(8):1119-25. PubMed ID: 22647270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved design and intranasal delivery of an M2e-based human influenza A vaccine.
    De Filette M; Fiers W; Martens W; Birkett A; Ramne A; Löwenadler B; Lycke N; Jou WM; Saelens X
    Vaccine; 2006 Nov; 24(44-46):6597-601. PubMed ID: 16814430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improving Cross-Protection against Influenza Virus Using Recombinant Vaccinia Vaccine Expressing NP and M2 Ectodomain Tandem Repeats.
    Wang W; Huang B; Wang X; Tan W; Ruan L
    Virol Sin; 2019 Oct; 34(5):583-591. PubMed ID: 31240620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.